湿性老年性黄斑部病变:KOL的洞察

本报告深入探讨了湿性老年黄斑部病变 (wAMD) 治疗的持续发展，并根据美国和欧洲的关键意见领袖 (KOL) 的见解提供了全面的分析。本报告对现有疗法和正在研发的疗法进行了深入回顾，重点介绍了 Eylea HD、Vabysmo 和 Avastin 等现有疗法以及 Axpaxli 和 OPT-302 等新兴疗法的优点和局限性。我们也探讨了家用光学相干断层扫描 (OCT) 和基因治疗等新发展对治疗模式的潜在影响。它还解决了管理 wAMD 方面的课题和未满足的需求，并对未来三到五年治疗前景的发展进行了展望。

主要问题

• 目前治疗湿性老年黄斑部病变 (wAMD) 的主要方法有哪些？
• 目前 wAMD 治疗方法的优点和缺点是什么？
• 目前 wAMD 治疗中尚未满足的需求和课题是什么？
• WAMD 目前正在开发哪些产品？
• 预计研发中的药物将如何影响 wAMD 的治疗途径？
• 未来 3 至 5 年内，wAMD 的治疗前景预计会发生怎样的变化？

领导品牌

调查手法

《治疗趋势》报告是透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，了解主要疾病领域的当前和未来治疗前景而编写的。 KOL 是根据严格的筛选标准精心挑选出来的，包括全球声誉、临床专业知识和其在治疗领域的影响力。每次访谈都遵循精心设计的讨论指南。这些指南是与 KOL 合作开发的，并经过行业专家的同行评审，以确保问题全面且与当前市场动态相关。透过在每份报告发布后12个月的持续市场监测，我们及时提供来自 KOL 的重大新闻事件、市场变化和市场发展的更新。

我们的报告的特点

FirstWord Reports 是值得信赖的行业领导者，专注于製药领域，为生物製药专业人士和决策者提供深入、可行的见解。我们深厚的行业知识使我们能够提供相关且有价值的见解，帮助我们的客户了解新兴趋势并有效地解决复杂的课题。我们的报告以广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解为后盾，为您提供所需的准确性和可信度。独家采访和数据以及持续的市场监控使我们能够全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的、数据驱动的决策，以在快速变化的行业中保持竞争力。

This report delves into the evolving landscape of wet age-related macular degeneration (wAMD) treatment, offering a comprehensive analysis based on insights from key opinion leaders (KOLs) across the USA and Europe. It provides an in-depth examination of both current and pipeline therapies, highlighting the advantages and limitations of existing treatments such as Eylea HD, Vabysmo, and Avastin, as well as emerging therapies like Axpaxli and OPT-302. The report explores the potential impact of new developments, including at-home optical coherence tomography (OCT) and gene therapies, on treatment paradigms. It also addresses the challenges and unmet needs in wAMD management, offering a forward-looking perspective on how the treatment landscape is expected to evolve over the next 3-5 years.

Key Questions Answered:

• 1. What treatments currently form the backbone of wet age-related macular degeneration (wAMD) therapy?
• 2. What are the advantages and disadvantages of current wAMD treatments?
• 3. What are the current unmet needs and challenges in treating wAMD?
• 4. Which products are currently in the development pipeline for wAMD?
• 5. How are pipeline therapies expected to impact treatment pathways for wAMD?
• 6. How is the treatment landscape for wAMD expected to evolve over the next 3-5 years?

Key Brands:

Partial List of Participating Experts:

• Consultant ophthalmic and retinal surgeon at the London Clinic and the Guthrie Clinic at Kings College Hospital, and Professor of retinal research at Kings College London, London, UK
• Professor of Ophthalmology, University Hospital of Bordeaux, Bordeaux, France
• Head of the Medical retina and imaging unit, Associate Professor of Ophthalmology at Universita Vita-Salute San Raffaele, Milan, Italy
• Director of artificial intelligence and imaging research, Doheny Eye Institute and Professor of Ophthalmology at the University of California- Los Angeles, USA
• Professor of Ophthalmology and Neuroscience at John Hopkins Wilmer eye institute
• Professor and Interim medical professor of the Hietzing clinic, Vienna, Austria

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.